Lubiprostone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lubiprostone" in English language version.

refsWebsite

Global rank English rank

5nih.gov

4^th place

4doi.org

2^nd place

2canada.ca

1,712^th place

1,063^rd place

2fda.gov

447^th place

338^th place

1wsj.com

79^th place

65^th place

1nice.org.uk

3,258^th place

2,666^th place

1harvard.edu

18^th place

17^th place

1web.archive.org

1^st place

1medlineplus.gov

1,581^st place

1,299^th place

1mayoclinic.org

1,610^th place

1,279^th place

1rxlist.com

7,927^th place

6,815^th place

1medscape.com

719^th place

636^th place

1drugs.com

399^th place

333^rd place

canada.ca

"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 2016-05-04.

doi.org

Webster LR, Brewer RP, Lichtlen P, Losch-Beridon T, Mareya S, Wang M (June 2018). "Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class". Pain Medicine. 19 (6): 1195–1205. doi:10.1093/pm/pnx212. PMID 29897589.
Li F, Fu T, Tong WD, Liu BH, Li CX, Gao Y, et al. (April 2016). "Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Mayo Clinic Proceedings. 91 (4): 456–468. doi:10.1016/j.mayocp.2016.01.015. PMID 27046523. Lubiprostone is a safe and efficacious drug for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation, with limited adverse effects in 3 months of follow-up.
Lacy BE, Levy LC (April 2007). "Lubiprostone: a chloride channel activator". Journal of Clinical Gastroenterology. 41 (4): 345–351. doi:10.1097/01.mcg.0000225665.68920.df. PMID 17413599.
Lacy BE, Levy LC (June 2008). "Lubiprostone: a novel treatment for chronic constipation". Clinical Interventions in Aging. 3 (2): 357–364. doi:10.2147/cia.s2938. PMC 2546479. PMID 18686757.

drugs.com

"Amitiza". The American Society of Health-System Pharmacists.

fda.gov

accessdata.fda.gov

"Highlights of Prescribing Information" (PDF). FDA. 2020.

fda.gov

"Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

harvard.edu

health.harvard.edu

"In the news: FDA approves one drug for irritable bowel syndrome but suspends another". Harvard Health. 2008-08-01.

mayoclinic.org

"Lubiprostone (Oral Route) Side Effects". Mayo Clinic. 2021.

medlineplus.gov

- "Lubiprostone: MedlinePlus Drug Information". medlineplus.gov. 2017. Lubiprostone is also used to treat irritable bowel syndrome with constipation... in women who are at least 18 years of age.

medscape.com

reference.medscape.com

"Amitiza (lubiprostone) dosing, indications, interactions, adverse effects, and more". reference.medscape.com.

nice.org.uk

"Final appraisal determination: Lubiprostone for treating chronic idiopathic constipation". National Institute for Health and Care Excellence. June 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Webster LR, Brewer RP, Lichtlen P, Losch-Beridon T, Mareya S, Wang M (June 2018). "Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class". Pain Medicine. 19 (6): 1195–1205. doi:10.1093/pm/pnx212. PMID 29897589.
Li F, Fu T, Tong WD, Liu BH, Li CX, Gao Y, et al. (April 2016). "Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Mayo Clinic Proceedings. 91 (4): 456–468. doi:10.1016/j.mayocp.2016.01.015. PMID 27046523. Lubiprostone is a safe and efficacious drug for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation, with limited adverse effects in 3 months of follow-up.
Lacy BE, Levy LC (April 2007). "Lubiprostone: a chloride channel activator". Journal of Clinical Gastroenterology. 41 (4): 345–351. doi:10.1097/01.mcg.0000225665.68920.df. PMID 17413599.
Lacy BE, Levy LC (June 2008). "Lubiprostone: a novel treatment for chronic constipation". Clinical Interventions in Aging. 3 (2): 357–364. doi:10.2147/cia.s2938. PMC 2546479. PMID 18686757.

ncbi.nlm.nih.gov

Lacy BE, Levy LC (June 2008). "Lubiprostone: a novel treatment for chronic constipation". Clinical Interventions in Aging. 3 (2): 357–364. doi:10.2147/cia.s2938. PMC 2546479. PMID 18686757.

rxlist.com

"Amitiza (Lubiprostone): Uses, Dosage, Side Effects, Interactions, Warning". RxList.

web.archive.org

"Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

wsj.com

"FDA Approves New Type of Drug To Treat Constipation in Adults". The Wall Street Journal. February 1, 2006.